Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06049134
PHASE4

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Sponsor: M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-10-06

Completion Date

2027-12-01

Last Updated

2026-03-09

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

PCV20

Given by Injection into the muscle

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States